<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412020001200006</article-id>
<article-id pub-id-type="doi">10.24245/gom.v88i12.4269</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Marcadores tumorales en cáncer de mama. Revisión sistemática]]></article-title>
<article-title xml:lang="en"><![CDATA[Tumor markers in breast cancer. Systematic review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bonilla-Sepúlveda]]></surname>
<given-names><![CDATA[Óscar Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,UniRemington  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>88</volume>
<numero>12</numero>
<fpage>860</fpage>
<lpage>869</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412020001200006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412020001200006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412020001200006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES:  El cáncer de mama es el tumor maligno más frecuente en mujeres de todo el mundo. Los marcadores tumorales aprobados por la FDA son el antígeno de cáncer 15-3 (CA15-3) y el antígeno carcinoembrionario, que se utilizan con frecuencia para la detección y control del cáncer de mama.  OBJETIVO:  Determinar la utilidad de los marcadores tumorales CA 15-3 y antígeno carcinoembrionario en la detección temprana de recurrencia, pronóstico y seguimiento de pacientes con cáncer de mama metastásico.  METODOLOGÍA:  Búsqueda sistemática de publicaciones en inglés en la base de datos Medline-PubMed con los términos: &#8220;biomarkers&#8221;, &#8220;tumor&#8221;, &#8220;tumor biomarkers&#8221;, &#8220;marker&#8221;, &#8220;tumor marker&#8221;, &#8220;breast neoplasms&#8221;, &#8220;breast&#8221;, &#8220;neoplasms&#8221;, &#8220;cancer&#8221;, &#8220;mucin-1&#8221;, &#8220;CA 15-3&#8221;, &#8220;carcinoembryonic antigen&#8221;. Se seleccionaron artículos originales, ensayos clínicos, revisiones, revisiones sistemáticas y metanálisis, publicados entre el 28 de marzo de 2015 y el 25 de marzo de 2020, que determinaran la utilidad del antígeno CA 15-3 y el antígeno carcinoembrionario en el cáncer de mama.  RESULTADOS:  Se seleccionaron para la redacción de este artículo 11 publicaciones trascendentales para determinar la utilidad de los marcadores tumorales en cáncer de mama.  CONCLUSIONES:  La utilidad de los marcadores tumorales antígeno 15-3 y antígeno carcinoembrionario es contradictoria y no completamente aceptada por las asociaciones de oncología y las guías internacionales; sin embargo, existe evidencia que confirma su utilidad como marcadores diagnósticos y pronósticos en el cáncer de mama.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND:  Breast cancer is the most frequent malignant tumor in women around the world. The FDA-approved tumor markers are cancer antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA), and are frequently used for the detection and control of breast cancer.  OBJECTIVE:  To present the current available information on the usefulness of tumor markers CA 15-3 and carcinoembryonic antigen in the detection of metastases and their prognostic value in breast cancer.  METHODOLOGY:  A systematic search of publications in English in the Medline-PubMed database was performed, using the terms: &#8220;biomarkers&#8221;, &#8220;tumor&#8221;, &#8220;tumor biomarkers&#8221;, &#8220;marker&#8221;, &#8220;tumor marker&#8221;, &#8220;breast neoplasms &#8220;,&#8221; breast &#8220;,&#8221; neoplasms &#8220;,&#8221; cancer &#8220;,&#8221; mucin-1 &#8220;,&#8221; ca 15 3 &#8220;,&#8221; carcinoembryonic antigen &#8220;. Original articles, clinical trials, reviews, systematic reviews and meta-analyzes, published between March 28, 2015 and March 25, 2020, were selected to determine the usefulness of the CA 15-3 antigen and carcinoembryonic antigen in breast cancer.  RESULTS:  Eleven publications that were relevant to determine the usefulness of tumor markers in breast cancer were selected for the writing of this article.  CONCLUSIONS:  The utility of tumor markers Antigen 15-3 and carcinoembryonic antigen is contradictory, and not fully accepted by oncology associations and international guidelines, however there is evidence that confirms their utility as diagnostic and prognostic markers in breast cancer.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Biomarcadores]]></kwd>
<kwd lng="es"><![CDATA[marcadores tumorales]]></kwd>
<kwd lng="es"><![CDATA[mucina -1]]></kwd>
<kwd lng="es"><![CDATA[antígeno carcinoembrionario]]></kwd>
<kwd lng="es"><![CDATA[neoplasia mama]]></kwd>
<kwd lng="es"><![CDATA[cáncer]]></kwd>
<kwd lng="en"><![CDATA[Biomarkers]]></kwd>
<kwd lng="en"><![CDATA[Tumor markers]]></kwd>
<kwd lng="en"><![CDATA[Mucin -1]]></kwd>
<kwd lng="en"><![CDATA[Embryonal carcinogen antigen]]></kwd>
<kwd lng="en"><![CDATA[Breast cancer]]></kwd>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<source><![CDATA[Cancer today]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Redig]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[McAllister]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer as a systemic disease a view of metastasis. J. Intern]]></article-title>
<source><![CDATA[Med]]></source>
<year>2013</year>
<volume>274</volume>
<page-range>113-26</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sundquist]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved survival in metastatic breast cancer 1985-2016]]></article-title>
<source><![CDATA[Breast]]></source>
<year>2016</year>
<volume>31</volume>
<page-range>46-50</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taplin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mammography facility characteristics associated with interpretive accuracy of screening mammography]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2008</year>
<volume>100</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>876-87</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mandelblatt]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2009</year>
<volume>151</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>738-47</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum tumor markers in breast cancer: are they of clinical value?]]></article-title>
<source><![CDATA[Clin. Chem]]></source>
<year>2006</year>
<volume>52</volume>
<page-range>345-51</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor markers in breast cancer -European Group on Tumor Markers recommendations]]></article-title>
<source><![CDATA[Tumour Biol]]></source>
<year>2005</year>
<volume>26</volume>
<page-range>281-93</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumour marker measurements in the diagnosis and monitoring of breast cancer]]></article-title>
<source><![CDATA[Cancer Treat. Rev]]></source>
<year>2000</year>
<volume>26</volume>
<page-range>91-102</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer]]></article-title>
<source><![CDATA[J. Clin. Oncol]]></source>
<year>2007</year>
<volume>25</volume>
<page-range>5287-312</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoembryonic antigen gene family: molecular biology and clinical perspectives]]></article-title>
<source><![CDATA[J Clin Lab Anal]]></source>
<year>1991</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>344-66</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sulekha Dhanisha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucins: structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets]]></article-title>
<source><![CDATA[Crit Rev Oncol Hematol]]></source>
<year>2017</year>
<volume>122</volume>
<page-range>98-122</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kufe]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential reactivity of a novel monoclonal antibody (df3) with human malignant versus benign breast tumors]]></article-title>
<source><![CDATA[Hybridoma]]></source>
<year>1984</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>223-32</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients]]></article-title>
<source><![CDATA[J Clin Investig]]></source>
<year>1985</year>
<volume>75</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1671-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gendler]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MUC1, the renaissance molecule]]></article-title>
<source><![CDATA[J Mammary Gland Biol Neoplasia]]></source>
<year>2001</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>339-53</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2011</year>
<volume>30</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1449-59</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hollingsworth]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Swanson]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucins in cancer: protection and control of the cell surface]]></article-title>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2004</year>
<volume>4</volume>
<page-range>45</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haddon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hugh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad]]></article-title>
<source><![CDATA[Clin Exp Metas]]></source>
<year>2015</year>
<volume>32</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>393-403</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MUC1 oncoprotein stabilizes and activates estrogen receptor a]]></article-title>
<source><![CDATA[Mol Cell]]></source>
<year>2006</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>295-305</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merikhian]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer]]></article-title>
<source><![CDATA[Expert Rev Anticancer Ther]]></source>
<year>2017</year>
<volume>17</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>607-13</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Genzen]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2018</year>
<volume>167</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>269-76</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gold]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Freedman]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques]]></article-title>
<source><![CDATA[J Exp Med]]></source>
<year>1965</year>
<volume>21</volume>
<page-range>439-62</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hammarström]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues]]></article-title>
<source><![CDATA[Semin Cancer Biol]]></source>
<year>1999</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>67-81</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Charbonneau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Stanners]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of carbohydrate structures in CEA-mediated intercellular adhesion]]></article-title>
<source><![CDATA[Cell Adhes Commun]]></source>
<year>1999</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>233-44</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kabel]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor markers of breast cancer new prospective]]></article-title>
<source><![CDATA[J Oncol Sci]]></source>
<year>2017</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-11</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stern]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2005</year>
<volume>174</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>6692-701</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicolini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carpi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postoperative follow-up of breast cancer patients overview and progress in the use of tumor markers]]></article-title>
<source><![CDATA[Tumour Biol]]></source>
<year>2000</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>235-48</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Hanlon]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>1995</year>
<volume>71</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1288-91</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Uehara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer]]></article-title>
<source><![CDATA[Int J Clin Oncol]]></source>
<year>2008</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>447-51</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maric]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor markers in breast cancer -evaluation of their clinical usefulness]]></article-title>
<source><![CDATA[Coll Antropol]]></source>
<year>2011</year>
<volume>35</volume>
<page-range>241-7</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardoso]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inconsistent criteria used in American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2008</year>
<volume>26</volume>
<page-range>2058-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="">
<collab>NCCN</collab>
<source><![CDATA[Breast cancer 2018]]></source>
<year>2018</year>
<edition>Version 4</edition>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Largillier]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic factors in 1038 women with metastatic breast cancer, Ann]]></article-title>
<source><![CDATA[Oncol]]></source>
<year>2008</year>
<volume>19</volume>
<page-range>2012-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mosconi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival, quality of life and breast cancer Ann]]></article-title>
<source><![CDATA[Oncol]]></source>
<year>2001</year>
<volume>12</volume>
<page-range>S15-9</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stieber]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer A retrospective analysis of kinetics on 743 breast cancer patients]]></article-title>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2015</year>
<volume>448</volume>
<page-range>228-31</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer]]></article-title>
<source><![CDATA[Breast]]></source>
<year>2014</year>
<volume>23</volume>
<page-range>88-93</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomlinson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumour marker CA15-3 possible uses in the routine management of breast cancer. Eur]]></article-title>
<source><![CDATA[J. Cancer]]></source>
<year>1995</year>
<volume>31A</volume>
<page-range>899-902</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soletormos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA]]></article-title>
<source><![CDATA[Eur. J. Cancer]]></source>
<year>2004</year>
<volume>40</volume>
<page-range>481-6</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colomer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases Res]]></article-title>
<source><![CDATA[Breast Cancer Res. Treat]]></source>
<year>1989</year>
<volume>13</volume>
<page-range>123-33</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guadagni]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study]]></article-title>
<source><![CDATA[Clin. Cancer Res]]></source>
<year>2001</year>
<volume>7</volume>
<page-range>2357-62</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jager]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer and clinical utility of CA 15-3 and CEA Scand. J. Clin. Lab. Invest]]></article-title>
<source><![CDATA[Suppl]]></source>
<year>1995</year>
<volume>221</volume>
<page-range>87-92</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Jarallah]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma]]></article-title>
<source><![CDATA[Eur. J. Surg. Oncol]]></source>
<year>1993</year>
<volume>19</volume>
<page-range>74-9</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Engel]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer]]></article-title>
<source><![CDATA[Geburtshilfe Frauenheilkd]]></source>
<year>1988</year>
<volume>48</volume>
<page-range>309-12</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coveney]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical value of CEA and CA 15-3 in breast cancer management]]></article-title>
<source><![CDATA[Int. J. Biol. Markers]]></source>
<year>1995</year>
<volume>10</volume>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ertl]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[CA125 in the early detection of metastatic breast cancer]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Poznak]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer American Society of Clinical Oncology. Clinical Practice Guidelines]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2015</year>
<volume>33</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2695-704</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer A meta-analysis including 12,993 patients]]></article-title>
<source><![CDATA[Dis Markers]]></source>
<year>2018</year>
<volume>2018</volume>
<page-range>9863092</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients A Meta-Analysis]]></article-title>
<source><![CDATA[Med Sci Monit]]></source>
<year>2016</year>
<volume>22</volume>
<page-range>3154-62</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Di Gioia]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Blankenburg]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Nagel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Heinemann]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Stieber]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor markers in the early detection of tumor recurrence in breast cancer patients CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3]]></article-title>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2016</year>
<volume>461</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Jing]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer]]></article-title>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2017</year>
<volume>470</volume>
<page-range>51-5</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fujimoto]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Higuchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nishimukai]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Miyagawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ozawa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bun]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Imamura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Miyoshi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy]]></article-title>
<source><![CDATA[J Surg Oncol]]></source>
<year>2018</year>
<volume>118</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>228-37</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicolini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carpi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Morganti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzotti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Barak]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Duffy]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An individual reference limit of the serum CEA-TPA-CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer]]></article-title>
<source><![CDATA[Cancer Manag Res]]></source>
<year>2018</year>
<volume>10</volume>
<page-range>6879-86</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bayo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Castaño]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of blood markers for early breast cancer diagnosis]]></article-title>
<source><![CDATA[Clin Transl Oncol]]></source>
<year>2018</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>467-75</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Imamura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes]]></article-title>
<source><![CDATA[World J Surg Oncol]]></source>
<year>2018</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nam]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry]]></article-title>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2019</year>
<volume>177</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>669-78</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
